New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.

A novel series of 3-morpholino rifamycins in which the C25 acetate group was replaced by a carbamate group were prepared and found to exhibit significantly improved antimicrobial activity than rifampin against Mycobacterium smegmatis. Further characterization of such compounds suggests that relatively large groups attached to the rifamycin core via a C25 carbamate linkage prevent inactivation via ribosylation of the C23 alcohol as catalyzed by the endogenous rifampin ADP-ribosyl transferase of M. smegmatis. SAR studies of the C25 carbamate rifamycin series against M. smegmatis and other bacteria are reported.

[1]  A. Morris,et al.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease , 1993, Antimicrobial Agents and Chemotherapy.

[2]  P. Schultz,et al.  1,1'-carbonylbis(3-methylimidazolium) triflate: an efficient reagent for aminoacylations , 1989 .

[3]  H. Floss,et al.  Rifamycin-mode of action, resistance, and biosynthesis. , 2005, Chemical reviews.

[4]  C. Tribuddharat,et al.  Integron-Mediated Rifampin Resistance inPseudomonas aeruginosa , 1999, Antimicrobial Agents and Chemotherapy.

[5]  S. Iwasaki,et al.  ADP-Ribosylation as an Intermediate Step in Inactivation of Rifampin by a Mycobacterial Gene , 1999, Antimicrobial Agents and Chemotherapy.

[6]  G. Acocella.  Pharmacokinetics and metabolism of rifampin in humans. , 1983, Reviews of Infectious Diseases.

[7]  N. Morisaki,et al.  Structures of ADP-ribosylated rifampicin and its metabolite: intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756. , 2000, The Journal of antibiotics.

[8]  H. Kinashi,et al.  A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb Streptomyces coelicolor A3(2) chromosome , 1996, Molecular microbiology.

[9]  H. Bickel,et al.  Zur Kenntnis von Rifamycin‐S.‐Reaktionen des Ansaringes. Modifikationen von Antibiotica, 8. Mitteilung [1] , 1973 .

[10]  W. Wehrli,et al.  CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria. , 1987, The Journal of antibiotics.

[11]  E. Dabbs,et al.  Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic , 1997, Antimicrobial agents and chemotherapy.

[12]  C. Jamis-Dow,et al.  Rifampin and rifabutin and their metabolism by human liver esterases. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[14]  G. Gallo,et al.  Acetyl migration in rifampicin. , 1968, Journal of medicinal chemistry.

[15]  R. Chaisson.  Treatment of Chronic Infections with Rifamycins: Is Resistance Likely To Follow? , 2003, Antimicrobial Agents and Chemotherapy.

[16]  Naohiro Matsugaki,et al.  Allosteric Modulation of the RNA Polymerase Catalytic Reaction Is an Essential Component of Transcription Control by Rifamycins , 2005, Cell.

[17]  T. Inaba,et al.  Identification of enzymes responsible for rifalazil metabolism in human liver microsomes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  S. Iwasaki,et al.  Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation , 1995, Antimicrobial agents and chemotherapy.

[19]  A. Segre,et al.  Synthesis, Reactivity Studies, and X‐ray Crystal Structure of (11R)‐25‐O‐Deacetyl‐11‐deoxo‐11‐hydroxy‐21,23‐O‐isopropylidenerifamycin S , 1990 .